Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patientsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined how different combined antiretroviral therapy (cART) regimens affect bacterial translocation and gut microbiota composition in HIV-infected patients. Prior work had shown that increased bacterial translocation and altered gut microbiota persist in HIV infection despite cART, contributing to immune activation and inflammation, but the role of specific drug combinations had not been investigated. Researchers measured soluble markers of bacterial translocation and inflammation and analyzed gut microbiota using 16S rDNA pyrosequencing (Illumina MiSeq).
Who was studied?
The cross-sectional study included 45 HIV-infected patients on cART, divided into three regimen groups: NRTIs plus protease inhibitors (n = 15), NRTIs plus non-nucleoside reverse transcriptase inhibitors (n = 22), and NRTIs plus integrase strand transfer inhibitors (INSTIs, n = 8). Also included were 5 untreated HIV-infected patients and 21 non-infected volunteers as comparison groups.
What were the most important findings?
The NRTIs plus INSTIs regimen was associated with systemic inflammation levels similar to those seen in uninfected controls, distinguishing it from the other cART combinations. HIV infection was linked to a reduction in fecal bacterial diversity. The abstract text was truncated, so further comparative details on translocation markers and microbiota composition across regimens are not available here.
What are the greatest implications of this study?
The findings suggest that the specific composition of a cART regimen, not just cART use in general, may influence residual inflammation and gut microbiota disruption in people living with HIV. This raises the possibility that regimens including INSTIs could offer advantages for reducing systemic inflammation compared to other combinations. Further research is needed to confirm these differential effects and clarify their clinical significance.